PhaseV Secures $50M Series A to Advance AI-Driven Clinical Development

PhaseV partners with over 30 pharma, biotech sponsors, and CROs across therapeutic areas like oncology, neurology, immunology, GI, rare diseases, and more.

PhaseV Secures $50M Series A to Advance AI-Driven Clinical Development
Source: PhaseV

Company Name: PhaseV
Location: Boston, MA
Industry: Health Tech

Funding Details:

  • Amount: $50M
  • Round: Series A
  • Investors:
    • Co-Leads: Accel and Insight Partners
    • Participants: Viola Ventures, EXOR, LionBird
  • Total Funding to Date: $65M

Purpose of Investment:

  • Scale operations
  • Accelerate product development across its clinical AI platform

Leadership:

Product:
PhaseV delivers an AI/ML-powered platform that supports end-to-end clinical development with four core applications:

  • Trial Optimizer: Optimizes Bayesian, adaptive, and fixed clinical trials.
  • Causal ML: Identifies heterogeneous treatment effects and pinpoints the most promising patient subpopulations and endpoints.
  • Causal Disease Modeling: Guides new R&D initiatives and lifecycle strategies.
  • Clinical Operations: Offers site selection, performance analytics, virtual control arm integration, and real-time monitoring using causal ML.

About Company:
PhaseV partners with over 30 pharma, biotech sponsors, and CROs across therapeutic areas like oncology, neurology, immunology, GI, rare diseases, and more. Its vertical AI platform is reshaping how trials are designed, optimized, and executed—unlocking deeper insights and faster development paths.

Read next